← Back to Screener
Psyence Biomedical Ltd. Common Shares (PBM)
Price$3.51
Growth ScoreA
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-102.07%
Price vs S&P 500 (4W)-37.20%
VGM Score66.79
Market Capitalization$3.59M
P/E Ratio (Annual)3.55x
All Metrics
Book Value / Share (Quarterly)$247.64
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-10.58
Price vs S&P 500 (YTD)-96.24%
EPS (TTM)$1612.06
10-Day Avg Trading Volume0.11M
EPS Excl Extra (TTM)$1612.06
EPS (Annual)$1631.92
ROI (Annual)15.05%
Cash / Share (Quarterly)$149.21
P/E Basic Excl Extra (TTM)13.88x
EPS Growth (5Y)143.93%
P/E Normalized (Annual)3.55x
ROA (Last FY)13.83%
EBITD / Share (TTM)$-39.68
Cash Flow / Share (Annual)$-2057.21
P/B Ratio0.30x
P/B Ratio (Quarterly)0.50x
Net Income / Employee (Annual)$84,300
Net Interest Coverage (TTM)-141.21x
ROA (TTM)-5.88%
EPS Incl Extra (Annual)$1631.92
Current Ratio (Annual)11.04x
Quick Ratio (Quarterly)7.82x
3-Month Avg Trading Volume1.92M
52-Week Price Return-98.24%
P/E Incl Extra (TTM)13.88x
Revenue / Employee (TTM)$0
52-Week High$468.38
EPS Excl Extra (Annual)$1631.92
26-Week Price Return-94.14%
Quick Ratio (Annual)10.61x
13-Week Price Return37.11%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.09x
Enterprise Value$-3.56M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$3370.97
3-Month Return Std Dev259.03%
Net Income / Employee (TTM)$21,500
ROE (Last FY)15.05%
Net Interest Coverage (Annual)-92.58x
EPS Basic Excl Extra (Annual)$1631.92
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$1612.06
ROI (TTM)-6.35%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-122.60%
P/E Ratio (TTM)13.88x
Year-to-Date Return-88.08%
5-Day Price Return-16.23%
EPS Normalized (Annual)$1631.92
ROA (5Y Avg)-960.97%
Month-to-Date Return-15.42%
EBITD / Share (Annual)$-5901.21
EPS Growth (3Y)345.96%
P/E Excl Extra (TTM)13.88x
EPS Basic Excl Extra (TTM)$1612.06
P/B Ratio (Annual)0.40x
Book Value / Share (Annual)$3693.41
Price vs S&P 500 (13W)28.85%
Beta1.65x
Revenue / Share (TTM)$0.00
ROE (TTM)-6.35%
52-Week Low$1.92
gGradeA
mGradeD
vgmGradeB
Show chart for
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PBMPsyence Biomedical Ltd. Common Shares | — | A | D | $3.51 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Psyence Biomedical Ltd is a biotechnology company developing psilocybin-based treatments for mental health conditions, including psychological trauma in palliative care. The company's product candidates are advancing through clinical trials to evaluate safety and efficacy. It operates a federally licensed cultivation facility in Southern Africa to produce natural psilocybin mushrooms for export and standardized pharmaceutical processing.